Pfizer Ltd. (India)

When Dinesh Patel became CEO of Protagonist Therapeutics in 2008, peptide therapeutics were largely overlooked, with only Novo Nordisk and Eli Lilly showing significant interest. Now, as the company a

When Michael Davidson, CEO of NewAmsterdam Pharma, describes his company’s lead asset obicetrapib, he frames it as a solution to one of cardiology’s most persistent challenges: managing residual cardi

Bayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science and consumer health businesses, and in 2024 pharma showed t

Pharma firms operating in India may need to make certain key modifications to their current data privacy programs, including adapting newer controls, to align with the country’s digital personal data